FN2 Earnings Intelligence
Gilead Sciences, Inc. earnings overview
Latest Gilead Sciences, Inc. (GILD) earnings intelligence, including the newest scorecard, market reaction, and transcript analysis.
Gilead Sciences, Inc.
Q2 results support a constructive growth thesis for Gilead: HIV, oncology and liver-disease products all contributed, and management raised the HIV outlook. The evidence is strongest near term; longer-term support depends on execution across launches, approvals, pipeline development and acquisitions.
Gilead Sciences, Inc.
Gilead delivered a solid Q1 2026 beat driven by 10% HIV growth and accelerating Yes2Go adoption, raising full-year revenue guidance by $400 million. Despite the beat, the stock sold off with a -2.9% abnormal move and continued downside drift, suggesting the market had already priced in the positive trajectory. The multi-franchise strategy spans HIV, oncology, liver disease, and cell therapy, with key FDA decisions on Biclen (August 2026), anitocel (December 2026), and Hepcludex (this quarter) as near-term catalysts. The Arcellx and Tubulis acquisitions bolster the ADC and CAR-T pipeline but add integration risk. With the stock at $133.83 versus a consensus target of $159.22, the bullish thesis depends on Yes2Go reaching its $1 billion target, successful Trodelvy label expansions, and clean regulatory execution across multiple pending decisions.
Gilead Sciences, Inc.
The call supports the view that resilient demand and pipeline execution can underpin Gilead's growth over the next year, but the evidence is balanced by cell-therapy competition, pricing pressure, regulatory timing and possible YES2GO cannibalization.
Gilead Sciences, Inc.
The latest analysis supports a cautiously constructive view of Gilead’s growth setup: resilient HIV demand, early Yeztugo coverage and Livdelzi momentum are tangible supports, while policy headwinds and execution-dependent pipeline opportunities keep the longer-term case conditional.
Gilead Sciences, Inc.
The current analysis supports a constructive near-term growth thesis for Gilead: Yeztugo's early launch, continued HIV franchise momentum, and pipeline progress were associated with raised guidance. The thesis remains conditional on sustained adoption, reimbursement, policy stability, and clinical execution.
Gilead Sciences, Inc.
The quarter supports a mixed but constructive operating picture: HIV and liver disease demand and pipeline progress provide growth support, while Veklury weakness, policy changes, competition, and launch execution remain material constraints.
Gilead Sciences, Inc.
The supplied analysis supports a constructive but qualified view: strong HIV demand, upcoming lenacapavir commercialization, Livdelzi expansion, and oncology and cell-therapy programs provide potential growth drivers, while reimbursement changes and execution risks temper confidence.
Get the GILD recap when the next report posts
One email per quarter with the scorecard, the market reaction and what changed on the call. No account needed.